HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakanishi, R. Articles by Yasumoto, K. Search for Related Content PubMed PubMed Citation Articles by Nakanishi, R. Articles by Yasumoto, K.

Ann Thorac Surg 1995;60:635-639
© 1995 The Society of Thoracic Surgeons

---

Original Articles: General Thoracic

Minimal Dose of Cyclosporin A for Tracheal Allografts

Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

Accepted for publication April 13, 1995.

Background. Minimizing immunosuppression after allotransplantation is desirable.

Methods. We assessed the minimal dose of cyclosporin A for viable tracheal allografts in 50 dogs. Each tracheal transplant, consisting of a six-ring segment of cervical trachea, was harvested and heterotopically implanted into the omentum. In group I (n = 10), transplantation into each dog's own omentum was performed as a control. The remaining 40 tracheal segments were randomly assigned to four recipient groups receiving either no treatment (group II, n = 10), 10 mg • kg^-1 • day^-1 of cyclosporin A (group III, n = 10), 15 mg • kg^-1 • day^-1 of cyclosporin A (group IV, n = 10), or 20 mg • kg^-1 • day^-1 of cyclosporin A (group V, n = 10). After 10 or 28 days, the tracheal segments were evaluated histologically.

Results. Epithelial regeneration in group IV was significantly better than that in groups I, II, or III on posttransplantation day 10. Only group IV showed no difference in epithelial viability from group I on posttransplantation day 28. In terms of vascularity, groups IV and V exhibited no differences from group I as evidenced by vascular endothelial morphology.

Conclusions. We conclude that an appropriate dose of 15 mg • kg^-1 • day^-1 of cyclosporin A may be used to maintain tracheal allograft viability.

This article has been cited by other articles:

				R. Nakanishi and K. Yasumoto Multiglycosidorum tripterygii versus Tacrolimus for rat tracheal allografts Eur. J. Cardiothorac. Surg., October 1, 2005; 28(4): 588 - 593. [Abstract] [Full Text] [PDF]

				W. Klepetko, G. M. Marta, W. Wisser, E. Melis, A. Kocher, G. Seebacher, C. Aigner, and S. Mazhar Heterotopic tracheal transplantation with omentum wrapping in the abdominal position preserves functional and structural integrity of a human tracheal allograft J. Thorac. Cardiovasc. Surg., March 1, 2004; 127(3): 862 - 867. [Abstract] [Full Text] [PDF]

				M. Hashimoto, R. Nakanishi, M. Umesue, H. Muranaka, M. Hachida, and K. Yasumoto Feasibility of cryopreserved tracheal xenotransplants with the use of short-course immunosuppression J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 0241 - 248. [Abstract] [Full Text] [PDF]

				R. Nakanishi, M. Umesue, M. Hashimoto, H. Muranaka, M. Hachida, and K. Yasumoto Limit of warm ischemia time before cryopreservation in rat tracheal isografts Ann. Thorac. Surg., December 1, 2000; 70(6): 1880 - 1884. [Abstract] [Full Text] [PDF]

				R. Nakanishi, M. Hashimoto, H. Muranaka, M. Umesue, H. Kohno, and K. Yasumoto MAXIMAL PERIOD OF CRYOPRESERVATION WITH THE BICELL BIOFREEZING VESSEL FOR RAT TRACHEAL ISOGRAFTS J. Thorac. Cardiovasc. Surg., June 1, 1999; 117(6): 1070 - 1076. [Abstract] [Full Text] [PDF]

				R. Nakanishi, N. Nagaya, T. Yoshimatsu, T. Hanagiri, and K. Yasumoto OPTIMAL DOSE OF BASIC FIBROBLAST GROWTH FACTOR FOR LONG-SEGMENT ORTHOTOPIC TRACHEAL AUTOGRAFTS J. Thorac. Cardiovasc. Surg., January 1, 1997; 113(1): 26 - 36. [Abstract] [Full Text]